A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Inclusion Criteria:

   - Confirmed and active Waldenstrom's Macroglobulinemia requiring treatment.

   - Ambulatory and capable of all selfcare. Up and about more than 50% of waking hours.

   - Adequate organ function.

   - Detectable CD20 positive of the tumor cells.

   - Measurable disease as defined by a monoclonal IgM paraprotein level greater than 1000
   mg/dL.

Exclusion Criteria:

   - Treatment of WM within the past 28 days.

   - Treatment with rituximab or alemtuzamab within the past 3 months.

   - Certain heart problems, chronic or current active infection not controlled with oral
   antibiotics, other current cancer or within last 5 years.

   - Current participation in another interventional clinical study.

   - Lactating or pregnant women or female patients of child-bearing potential (or male
   patients with such partners) not willing to use adequate contraception.

   - Active cerebrovascular disease.